CLARITY AND FOCUS FOR PATIENTS WITH SCHIZOPHRENIA

The first prescription digital therapeutic designed to treat schizophrenia

THRIVETM for Schizophrenia

Pear Therapeutics has developed THRIVETM, a prescription digital therapeutic to be used in conjunction with medication for treating schizophrenia

Thrive_Hands-1024x640

Medication Plus Patient-Facing Smartphone Application

Clinician Dashboard1

Clinician-Facing Web Interface

What is ThriveTM?

  • THRIVETM is a clinically validated prescription digital therapeutic applying evidence-based, multi-modal and reinforcement therapy. It is comprised of a patient-facing smartphone application and clinician-facing web interface.
  • THRIVETM is a prescription digital therapeutic that provides 24/7, real-time patient monitoring and support.
  • THRIVETM provides real-time interventions targeting positive symptoms of schizophrenia including hallucinations and delusions, and also provides support for schizophrenia-related mood disorders.

ThriveTM as A Prescription Digital Therapeutic for Treating Schizophrenia

THRIVETM enhances the efficacy of atypical anti-psychotics for schizophrenia

A 30-day trial of THRIVETM shows significant reduction in the following:

Graph 1
Graph 2
Graph 3
Graph 4
  • 33 patients on anti-psychotic medications were given access to THRIVETM and their symptoms were evaluated for 30 days.
  • After 30 days of therapy, patients showed an average 8% reduction in Positive and Negative Syndrome Scale (PANSS).
  • Patients were highly satisfied with THRIVETM, interacting with the application an average of 5.2 times per day. 63% of the use was initiated by patients.

Ben-Zeev et al. Schizophrenia Bull. 2014.

Pear's Academic Partners are Currently Conducting Additional Trials Examining Efficacy in Schizophrenia

  • Currently concluding a 3-year multi-site/multi state study in which 400+ patients with schizophrenia will receive THRIVETM for 6 months of treatment post-discharge from an episode requiring hospitalization
  • In 2016, Pear’s academic partners will conduct a randomized controlled trial (RCT, n=40 people with schizophrenia) of THRIVETM vs Treatment as Usual
  • In 2016, Pear’s academic partners will start a 2.5 year RCT comparing THRIVETM to a clinic-based group intervention (n=160 people with severe mental illness)

For more information, please contact us

THRIVETM is not yet FDA-cleared or available in the United States